Jai Hind Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.10 Cr
- Paid Up Capital ₹ 1.09 Cr
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.45 Cr
- Revenue Growth 6.20%
- Profit Growth 92.10%
- Ebitda 55.81%
- Net Worth 25.55%
- Total Assets 11.82%
About Jai Hind Pharma
Jai Hind Pharma Private Limited (JHPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 February 2016 (Eight years and 11 months 30 days old ). Its registered office is in Ranchi, Jharkhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.10 Cr and a paid-up capital of Rs 1.09 Cr.
The company currently has active open charges totaling ₹1.45 Cr.
Subhash Rajgaria, Sandeep Rajgariah, and Sanjay Rajgarhia serve as directors at the Company.
Company Details
-
Location
Ranchi, Jharkhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52311JH2016PTC003497
-
Company No.
003497
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Feb 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Jai Hind Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhash Rajgaria
|
Director | 16-Aug-2018 | Current |
|
Sandeep Rajgariah
|
Director | 16-Aug-2018 | Current |
|
Sanjay Rajgarhia
|
Director | 16-Aug-2018 | Current |
Financial Performance of Jai Hind Pharma.
Jai Hind Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.2% increase. The company also saw a substantial improvement in profitability, with a 92.1% increase in profit. The company's net worth Soared by an impressive increase of 25.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jai Hind Pharma?
In 2023, Jai Hind Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rajgaria Brothers Private LimitedSubhash Rajgaria, Sandeep Rajgariah and 1 more are mutual person
Charges (Loans)
₹1.45 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 1.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Feb 2020 | Others | ₹1.45 Cr | Open |
How Many Employees Work at Jai Hind Pharma?
Unlock and access historical data on people associated with Jai Hind Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jai Hind Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jai Hind Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
